This is a preview of subscription content, log in via an institution to check access.
Notes
The clinical trials, conducted in Canada and the US, were sponsored by Ferring Pharmaceuticals, US.
Reference
Lee C, et al. Safety of fecal microbiota, live-jslm (REBYOTA) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials. Therapeutic Advances in Gastroenterology : 12 Jun 2023. Available from: URL: https://journals.sagepub.com/doi/full/10.1177/17562848231174277
Rights and permissions
About this article
Cite this article
Faecal microbiota transplantation "safe, well tolerated" in recurrent C. difficile infection. Reactions Weekly 1967, 6 (2023). https://doi.org/10.1007/s40278-023-43813-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-43813-9